CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,816 enrolled
Drug / intervention
Leuprorelin Acetatedrug
Likely dose
Leuprorelin Acetate 11.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02134977
NCT02134977N/ACompleted
CompareCT.gov

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"

Takeda·observational·Posted May 9, 2014·Updated Oct 18, 2016

In Brief

An observational study evaluating Leuprorelin Acetate for Breast Cancer. Completed, enrolled 2,816 participants.

Detailed Summary

The purpose of this survey is to examine the effect on quality of life (QOL) improvement and convenience of switching to leuprorelin acetate 3 months depot 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) from a 4-week adjuvant therapy with a luteinizing hormone-releasing hormone analog (LH-RHa) 1 month depot over 48 weeks in premenopausal breast cancer participants in daily medical practice. Influence of condition of estrogen receptor expression on the efficacy and safety of leuprorelin acetate SR 11.25 mg injection kit was also evaluated.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 9, 2014
Enrollment StartSep 1, 2011
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.1 years ago

Interventions

Leuprorelin Acetatedrug

Leuprorelin Acetate SR 11.25 mg Injection Kit